TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04228484

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GIP receptor antagonization
Description: GIP(3-30)NH2 infusion
Study: NCT00125450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Physiotherapy with Forced Expiratory Technique
Description: Chest Physiotherapy with Forced Expiratory Technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopharyngeal Aspiration
Description: Nasopharyngeal Aspiration
Study: NCT01461642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self management asthma plan indorsment.
Description: Subjects adherence to asthma self management plan will be monitored through web-based support.
Study: NCT00116688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Study: NCT02074202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F- fluorocholine
Description: To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F- fluorodeoxyglucose
Description: To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
Study: NCT01719549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: * Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule~* Study drug: TKI258 capsule~* Dose: 500mg p.o. qd~* Every 3 weeks
Study: NCT01775670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Off-the-shelf splint
Description: Subjects will use an off-the-shelf splint

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OT Splint
Description: Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists.
Study: NCT02880267

Intervention type: DEVICE
Group type: OTHER
Intervention: CGM
Description: Glucose challenge during a clinic session to assess CGM performance compared to a laboratory reference measurement.
Study: NCT04155047

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Glyocopyrrolate Inhalation Solution administered by Magnair
Description: glycopyrrolate Inhalation Solution 25mcg, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administered by Magnair
Description: Placebo Inhalation Solution
Study: NCT04120571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Audiological Intervention Device (SleepAID)
Description: subtle sound stimulation in phase with the slow oscillations

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham control
Description: no noise
Study: NCT02689843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproterone compound + Spironolactone
Description: Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500mg three times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30mg once daily
Study: NCT04331678

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator App
Description: Participants will download and agree to use the study app at least once per week during the 3-month intervention period.~The app allows participants to invite a network of friends and family to provide emotional and logistical support during their treatment.
Study: NCT01068275

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar plexus catheter
Description: lumbar plexus catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral nerve catheter
Description: femoral nerve catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single-shot femoral block
Description: single-shot femoral block with 0.2% ropivacaine 0.3 ml/kg (max 20 ml)
Study: NCT03974139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Oral Tablet
Description: Day 1 to day 3: 500 mg/day Day 4 to day 6: 500 mg/twice a day Day 7 to day 9: 500 mg three times a day Day 10 until next lumbar puncture : 850 mg three times a day
Study: NCT03727542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adjustment of atrioventricular delay in DDD packers
Description: Atrioventricular delays are going to be adjusted as 60 milisecond shorter than the patients' native PR intervals in patients with already implanted permanent pacemakers.
Study: NCT00045526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03804489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aids
Description: Decision aids in helping the infant family to decide whether the infant will or will not receive the oral rotavirus vaccine.
Study: NCT01597609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sibutramine
Description: 10 mg, taken orally once per day for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sibutramine placebo
Description: taken orally once per day for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sibutramine placebo
Description: taken orally once per day for 12 weeks
Study: NCT02964325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirasol platelets (MIR PLTs)
Description: The final product to be transfused to the subject will be leukoreduced (LR), apheresis (Aph) single-donor platelets (PLTs) at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs. MIR PLTs will be treated with the Mirasol pathogen reduction technology system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference platelets (REF PLTs)
Description: The final product to be transfused to the subject will be LR-Aph single-donor PLTs at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs.
Study: NCT00400725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobex® Shampoo
Description: Clobex® Shampoo 0.05 % (W/W) topically to scalp for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clobex® Vehicle Shampoo
Description: Clobex® Vehicle Shampoo 0.05 % (W/W) topically to scalp up to 6 months.
Study: NCT00697099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component~Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study: NCT02880254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kurbo
Description: health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kurbo
Description: health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal Health Coach
Description: weekly health coach via facetime or Skype to motivate and counsel subjects during the weight loss process
Study: NCT02812186

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep to Moderate NMB
Description: Rocuronium infusion will be paused and the Train of Four (TOF) monitor will be set to every 1-2 min. Once the patient has achieved a moderate NMB state (one to two twitches), the infusion of the muscle relaxant will be resumed at a low dose to maintain the patient at this level of blockade.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Moderate to Deep NMB
Description: Rocuronium infusion will be increased in increments of 0.1-0.2 mg/kg/hr. and the TOF monitor will be set to every 1-2 min. Once the patient has no twitches and a PTC of 0-1 (deep NMB) the infusion will be adjusted to maintain the patient at this level of NMB.

Intervention type: DRUG
Group type: OTHER
Intervention: Rocuronium

Intervention type: DRUG
Group type: OTHER
Intervention: Rocuronium
Study: NCT02169440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIA 9-1067
Description: BIA 9-1067 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin 25 mg
Study: NCT00400725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobex® Shampoo
Description: Clobex® Shampoo 0.05% (W/W) topically to scalp up to 6 months.
Study: NCT04199559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells pulsed with antigen
Description: peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal
Study: NCT02169440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin 25 mg
Study: NCT02277483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAIS®
Description: 10 X 1,000 / twice a week
Study: NCT03799614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMBand lower dose
Description: Light-weight portable device that delivers low dose vibration to the arm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMBand higher dose
Description: Light-weight portable device that delivers higher dose vibration to the arm
Study: NCT00972621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrax II
Description: Viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viscoat
Description: Currently marketed viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber..
Study: NCT02958046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole/Domperidone
Description: DUOLANS 30/30 mg SR tablet per oral, one tablet daily
Study: NCT06329700

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Surgical removal of a part of the liver

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Surgical removal of a part of the liver
Study: NCT04220840

Intervention type: PROCEDURE
Intervention: Damage control strategy
Description: The damage control strategy constitutes a two stage procedure.~Emergency surgery:~limited resection oft he diseased colonic segment with oral and aboral blind closure, abdominal lavage, temporary vacuum assisted abdominal closure~Second look surgery (48-72 hours later):~reexploration with~1. definite reconstruction (Colorectal anastomosis -/+ diverting ileostomy vs. end colostomy)~2. lavage, vacuum assisted abdominal closure, third look 72 hours after emergency surgery

Intervention type: PROCEDURE
Intervention: Damage control strategy
Description: The damage control strategy constitutes a two stage procedure.~Emergency surgery:~limited resection oft he diseased colonic segment with oral and aboral blind closure, abdominal lavage, temporary vacuum assisted abdominal closure~Second look surgery (48-72 hours later):~reexploration with~1. definite reconstruction (Colorectal anastomosis -/+ diverting ileostomy vs. end colostomy)~2. lavage, vacuum assisted abdominal closure, third look 72 hours after emergency surgery
Study: NCT03264911

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin or Placebo
Description: Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin or Placebo
Description: Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment
Study: NCT00913848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
Study: NCT02137889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.
Study: NCT04075994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational Agent and heart rate and rhythm monitor
Description: Use of the Relational Agent and heart rate and rhythm monitor daily for 120 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Use of the WebMD app and heart rate and rhythm monitor daily for 120 days.
Study: NCT04073446

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation
Description: Patients eligible for SCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation
Description: Patients eligible for SCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation
Description: Patients eligible for SCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation
Description: Patients eligible for SCS
Study: NCT04391998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: oral tablet twice daily after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: oral tablet twice daily after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: oral tablet twice daily after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: 500 mg oral twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: 200 mg oral single dose
Study: NCT03152097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially available Diindolylmethane
Description: Commercially available Diindolylmethane is a compound derived from cruciferous vegetables (e.g. broccoli)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Commercially available Diindolylmethane
Description: Commercially available Diindolylmethane is a compound derived from cruciferous vegetables (e.g. broccoli)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A matching placebo capsule will be compounded by the UPMC Investigational Drug Service

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching placebo capsule will be compounded by the UPMC Investigational Drug Service
Study: NCT02942992

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Resistance exercise
Description: resistance exercise
Study: NCT02063672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix DCB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Uncoated Balloon Angioplasty Catheter
Description: PTA Catheter
Study: NCT00945841

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: inactivated split influenza vaccine
Description: 1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010
Study: NCT00236002

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70mgm once a week for one year
Study: NCT02324686

Intervention type: DRUG
Group type: OTHER
Intervention: vitamin K1
Description: Vitamin K1 400 mcg orally three times a week on dialysis days for four months
Study: NCT01547715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY conjugate vaccine
Description: All subjects received a single dose of Meningococcal ACWY conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY conjugate vaccine
Description: All subjects received a single dose of Meningococcal ACWY conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY conjugate vaccine
Description: All subjects received a single dose of Meningococcal ACWY conjugate vaccine
Study: NCT03353792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CL/AP system
Description: CL/AP system enabled insulin pump/CGM combination

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: usual diabetic care
Description: usual diabetic care (insulin pump therapy) along with CGM recording
Study: NCT01317147

Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass (RYGBP)
Study: NCT00372138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP + autologous thrombin
Description: simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
Study: NCT03056521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative information about pain
Description: It is information about analgesics, post operative pain, complications of pain, benefits of pain treatment and non pharmacologic treatment options.
Study: NCT00481884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RadiaPlexRx Gel
Description: RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquaphor Gel
Description: Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
Study: NCT00735709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated immediate-release vortioxetine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated immediate-release vortioxetine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated immediate-release vortioxetine tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules
Study: NCT01165307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills
Description: Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen sodium pills
Description: As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
Study: NCT04306016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory stimulation
Description: Sensory stimulation can be formed in different aspects, and the most important ones are visual stimulation and auditory stimulation. Visual stimulation interventions involved providing a calendar, clock or familiar objects such as photographs of family caregivers; while auditory stimulation included calling the name of patients, helping to orientate the time and location, introducing hospital information, the ICU surrounding and treatment, and communicating with patients, who could not talk due to artificial airway, through a blackboard and use of gestures.
Study: NCT03025035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV solution administered on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib administered orally twice a day
Study: NCT01165307

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovaSure® Radiofrequency Endometrial Ablation
Description: Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
Study: NCT02920190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months
Study: NCT02280434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBP-307

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02163395

Intervention type: DEVICE
Group type: OTHER
Intervention: FullCeram implant
Description: FullCeram implantation
Study: NCT01965327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1b
Description: Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.~All doses will be administered via subcutaneous injection.